Cherie,

This discussion is clearly not advancing anyone's understanding of the PML risk with Tysabri and risks a re-escalation of board tensions so let's just leave the risk calculations to the regulators. I will definitely respect the boards rules to avoid strained discussions. Given the number of patients at 18 months and two years of therapy, this should happen relatively soon and then we can decide who was correct and was incorrect in seeing through the mud.

-- Is not likely zero but a recognition that the numbers were not material given that the drug was relaunched in July 2006.

Chris